Michelle A Fravel1, Elizabeth Bald2, Mony Fraer3. 1. Department of Pharmacy Practice and Science, College of Pharmacy, The University of Iowa, 220 PHAR, 115 S. Grand Ave., Iowa City, IA, 52242, USA. michelle-fravel@uiowa.edu. 2. Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 3. Division of Nephrology and Hypertension, Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA.
Abstract
PURPOSE OF REVIEW: Hypertension and antihypertensive drug utilization are remarkably prevalent in ESRD patients. Management of blood pressure elevation in this population is complicated by many factors, including a multidimensional etiology, challenges in obtaining accurate and appropriately timed blood pressure measurements, highly specific drug dosing requirements, and a paucity of outcomes-based evidence to guide management decisions. The purpose of this review is to summarize and apply knowledge from existing clinical trials to enhance safe and effective use of antihypertensive agents in dialysis patients. RECENT FINDINGS: Two meta-analyses have established the benefit of antihypertensive therapy in ESRD. Data supporting the use of one antihypertensive class over another is less robust; however, beta-blockers have more clearly demonstrated improved cardiovascular outcomes in prospective randomized trials. Interdialytic home blood pressure monitoring has been demonstrated to be better associated with cardiovascular outcomes than clinic pre- or post-dialysis readings and should ideally be considered as a routine part of blood pressure management in this population. As data from small trials provides limited guidance for the management of hypertension in ESRD, more research is needed to guide medication selection and utilization. Specifically, large prospective randomized trails comparing cardiovascular outcomes of various medication classes and differing blood pressure targets are needed.
PURPOSE OF REVIEW: Hypertension and antihypertensive drug utilization are remarkably prevalent in ESRDpatients. Management of blood pressure elevation in this population is complicated by many factors, including a multidimensional etiology, challenges in obtaining accurate and appropriately timed blood pressure measurements, highly specific drug dosing requirements, and a paucity of outcomes-based evidence to guide management decisions. The purpose of this review is to summarize and apply knowledge from existing clinical trials to enhance safe and effective use of antihypertensive agents in dialysis patients. RECENT FINDINGS: Two meta-analyses have established the benefit of antihypertensive therapy in ESRD. Data supporting the use of one antihypertensive class over another is less robust; however, beta-blockers have more clearly demonstrated improved cardiovascular outcomes in prospective randomized trials. Interdialytic home blood pressure monitoring has been demonstrated to be better associated with cardiovascular outcomes than clinic pre- or post-dialysis readings and should ideally be considered as a routine part of blood pressure management in this population. As data from small trials provides limited guidance for the management of hypertension in ESRD, more research is needed to guide medication selection and utilization. Specifically, large prospective randomized trails comparing cardiovascular outcomes of various medication classes and differing blood pressure targets are needed.
Authors: Rajiv Agarwal; Arjun D Sinha; Maria K Pappas; Terri N Abraham; Getachew G Tegegne Journal: Nephrol Dial Transplant Date: 2014-01-06 Impact factor: 5.992
Authors: Martin Hausberg; Markus Kosch; Patrick Harmelink; Michael Barenbrock; Helge Hohage; Klaus Kisters; Karl Heinz Dietl; Karl Heinz Rahn Journal: Circulation Date: 2002-10-08 Impact factor: 29.690
Authors: Rajiv Agarwal; Allen R Nissenson; Daniel Batlle; Daniel W Coyne; J Richard Trout; David G Warnock Journal: Am J Med Date: 2003-09 Impact factor: 4.965
Authors: Ioannis Koulouridis; Mansour Alfayez; Thomas A Trikalinos; Ethan M Balk; Bertrand L Jaber Journal: Am J Kidney Dis Date: 2012-08-22 Impact factor: 8.860